NewTimeSpace丨BioRay Biopharmaceutical, China's Leading Autoimmune Disease Company, Files for Hong Kong IPO
BioRay Biopharmaceutical recently submitted its listing application to the Hong Kong Stock Exchange. According to Frost & Sullivan, the company has ranked first among Chinese pharmaceutical companies by autoimmune disease biologics revenue for two consecutive years since 2023. The prospectus shows it recorded revenue of RMB 1.623 billion and net profit of RMB 91 million in 2024, with a gross margin of 79.2%.
Zhejiang BioRay Biopharmaceutical Co., Ltd. (hereinafter referred to as "BioRay Biopharmaceutical") recently submitted its prospectus to the Hong Kong Stock Exchange, seeking a listing on the Main Board with Huatai International and J.P. Morgan as joint sponsors.
Tags：
- GF Guozheng Semiconductor Chip ETF(159801) Surges Over 1.4%, Approaching 3 Consecutive Days of Gains, with AUM Growth of RMB 25.8186 Million Over Past Week
- Fullgoal CSI Tourism Thematic ETF(159766) Rises 0.44% Intraday, with Average Daily Trading Volume of 487 Million Yuan in the Past Week
- Penghua Guozheng Semiconductor Chip ETF(159813) Surges Over 1.2%, Approaching 3 Consecutive Days of Gains
- AUM Increases by 370 Million Yuan in a Week,GF CSI All Share Power Public Service ETF(159611) Rises 0.73%
